El síndrome metabólico (SM) es una entidad compuesta por diversas alteraciones que confieren un aumento del riesgo cardiovascular y de diabetes a largo plazo. Sus características en pacientes con síndromes coronarios agudos (SCA) son prácticamente desconocidas. ObjetivosDeterminar la prevalencia, las características y el valor pronóstico del síndrome metabólico (SM) en los síndromes coronarios agudos (SCA). Evaluar su correlación con los factores de riesgo coronario (FRC) y los hábitos dietéticos y analizar una nueva definición recientemente propuesta. Material y métodosSe incluyeron pacientes consecutivos ingresados en Unidad Coronaria con infarto agudo de miocardio o angina inestable. Se diagnosticó SM en base a los criterios del NCEP-ATP III. La nueva definición analizada fue la propuesta por la International Diabetes Federation. ResultadosSe incluyeron en el estudio 239 pacientes. El SM estuvo presente en el 53,3 % de los casos y fue más frecuente en las mujeres (OR 2,53; IC 95%: 1,24-5,18) (p = 0,005). No presentó correlación significativa con el pronóstico hospitalario ni con los hábitos dietéticos. Su prevalencia según la nueva definición fue casi idéntica (53%) y si bien tuvo valor pronóstico en el análisis univariado, no lo conservó en el multivariado. ConclusionesLa prevalencia del SM en los SCA es más elevada que la informada para otras poblaciones. No parece tener valor pronóstico a corto plazo. La nueva definición no modificó su prevalencia ni agregó información pronóstica independiente.
Children with new-onset type 1 diabetes (T1DM) may experience some growth delay. To compare growth trajectories assessed by z-height and z-BMI over a 3-year follow-up period between children with new-onset T1DM and a control group without T1DM across multiple Latin American centers. A retrospective analysis of medical records was conducted over 3 years (2021–2024) in children with new-onset T1DM and their controls from ten Latin American centers, including age, sex, and anthropometric measures. A mixed-effects model was used to analyze z-height and z-BMI over three years. A total of 534 participants were included, comprising 245 children with T1DM (51.4
Background & Aims Several clinical risk models have been proposed to stratify hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis C virus (HCV) after sustained virologic response (SVR). However, validation efforts have focused on monocentric or country-specific cohorts, and it is unclear if clinical risk models can be broadly applied to global populations. We characterised regional variation in model performance for HCC risk stratification in post-SVR patients.Methods Four HCC clinical risk models (aMAP score, FIB-4 index, GES score, and Toronto HCC risk index [THRI]) were analysed in six real-world cohorts, which included 8796 post-SVR patients from different geographic regions globally. Model discrimination was assessed using Harrel's c-statistic index. HCC incidence rates were compared across low-, intermediate-, and high-risk groups for each model.Results Distributions of patient characteristics and HCC incidence rates varied across geographic regions. Predictive performances of models were comparable within each cohort despite the model with the highest c-statistics differing by regions. Performance was lower than those from original reports overall; c-statistics of models across most regions remained below 0.70.Conclusions There remains a continued need to improve discrimination and calibration of clinical models to stratify HCC risk in post-SVR patients. Accuracy of models may differ by geographic region, underscoring the importance of external validation to assess transportability of models and suggesting no single model can be universally applied.
The introduction of CDK4/6 inhibitors (iCDK4/6) in the adjuvant setting for hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer has expanded treatment options for high-risk patients. However, real-world data on eligibility for these therapies in Latin American populations remain limited. This retrospective study analyzed 334 patients with HR+/HER2- early breast cancer (stages I-III) treated at a Colombian cancer center (2022-2024). Eligibility criteria for adjuvant abemaciclib (monarch-E) and ribociclib (NATALEE) were applied. Clinicopathological characteristics and treatment patterns were assessed. Among abemaciclib-eligible patients (36.2%, n=121), 54.5% had ≥4 positive nodes and 45.5% met alternative high-risk criteria (1-3 nodes plus tumor size ≥5 cm or grade 3 or Ki67 ≥20%). Ribociclib-eligible patients (59%, n=197) included 53.8% with stage III disease and 12.7% with node-negative, grade 3 tumors. Compared to pivotal trials, our cohort had older median age (61 vs 51-58 years) and lower prevalence of grade 3 tumors (17.1% vs 30-40%). A substantial proportion of Colombian patients with early HR+/HER2- breast cancer qualify for adjuvant CDK4/6i, particularly those with nodal involvement. These findings highlight both the clinical opportunity and economic challenges of implementing these therapies in resource-limited settings, while underscoring the need for improved early detection to reduce advanced presentations. A. S. Golemba, S. P. Rodriguez Torres, R. F. Vargas Moranth, P. Mandó, A. A. Aguirre Santamaria. Characteristics of patients with HR+/HER2− early breast cancer eligible for adjuvant treatment with iCDK4/6: real-life evidence in a Colombian cancer center. [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-10-04.
